LINICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 398 JPY | +0.76% |
|
+2.58% | -24.91% |
| Sales 2024 | 12.31B 79.28M | Sales 2025 * | 12.6B 81.17M | Capitalization | 8.92B 57.47M |
|---|---|---|---|---|---|
| Net income 2024 | 338M 2.18M | Net income 2025 * | 600M 3.87M | EV / Sales 2024 | 0.72 x |
| Net cash position 2024 * | 3.93B 25.3M | Net cash position 2025 * | 5.08B 32.71M | EV / Sales 2025 * | 0.31 x |
| P/E ratio 2024 |
26.3
x | P/E ratio 2025 * |
14.8
x | Employees | 759 |
| Yield 2024 |
3.81% | Yield 2025 * |
4.05% | Free-Float | 45.77% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.76% | ||
| 1 week | -0.25% | ||
| Current month | -0.25% | ||
| 1 month | -4.10% | ||
| 3 months | +2.58% | ||
| 6 months | -23.61% | ||
| Current year | -24.91% |
1 week
394.00
403.00
1 month
383.00419.00
Current year
374.00553.00
1 year
374.00874.00
3 years
374.001 029.00
5 years
374.001 263.00
10 years
374.002 584.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kazuhiro Hatano
FOU | Founder | 59 | 05-06-06 |
| Director of Finance/CFO | 56 | 05-06-06 | |
Shiori Yamaguchi
CMP | Compliance Officer | 48 | 05-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kazuhiro Hatano
FOU | Founder | 59 | 05-06-06 |
| Director of Finance/CFO | 56 | 05-06-06 | |
Isao Sakamoto
BRD | Director/Board Member | 48 | 05-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 19 M€ | +8.14% | ||
| 0.00% | 17 M€ | +16.94% | - | |
| 0.00% | 140,441 M€ | +17.70% | ||
| 0.00% | 63,295 M€ | +17.72% | - | |
| 0.00% | 20,360 M€ | +16.46% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 398 | +0.76% | 6 800 |
| 24-06-06 | 395 | 0.00% | 8,300 |
| 24-06-05 | 395 | -0.50% | 6,900 |
| 24-06-04 | 397 | +0.76% | 11,900 |
| 24-06-03 | 394 | -1.25% | 9,000 |
Delayed Quote Japan Exchange, June 07, 2024 at 02:00 am EDT
More quotes
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
Calendar
2024-08-13
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.91% | 57.18M | |
| +55.55% | 59.28B | |
| +43.17% | 40.94B | |
| -4.71% | 40.17B | |
| -5.56% | 28.69B | |
| +13.76% | 26.63B | |
| -22.00% | 18.89B | |
| +31.50% | 12.46B | |
| +2.16% | 12.42B | |
| +25.70% | 12.26B |
- Stock Market
- Equities
- 2183 Stock
